Estás son las publicaciones más relevantes producidas por el Grupo CUETO:
- Estudio retrospectivo de diferentes opciones de tratamiento conservador con Bacilo de Calmette-Guérin en el carcinoma urotelial vesical T1G3: terapia de mantenimiento. Actas Urol Esp 2016;40(6):370-377.
- Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non–muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013Abrir en una ventana nueva Eur Urol 2015 Aug;68(2):256-62.
- Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.Abrir en una ventana nueva Eur Urol 2015 Mar;67(3):508-16.
- Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α.Abrir en una ventana nueva. J Urol. 2011 Jan;185(1):67-71
- The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk TablesAbrir en una ventana nueva Eur Urol 2011 Sep;60(3):423-30.
- Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring ModelAbrir en una ventana nueva J Urol 2009 Nov;182(5):2195-203
- Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008 May;53(5):992-1001.
- A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin CAbrir en una ventana nueva C. Eur Urol 2007 Nov;52(5):1398-406.
- Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and TIS bladder tumors than the standard dose? Results of a prospective randomized trialAbrir en una ventana nueva J Urol 2005 Oct;174(4 Pt 1):1242-7.
- Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Gue´rin with a reduced dose of 27 mg in superficial bladder cancerAbrir en una ventana nueva BJU Int 2002 May;89(7):671-80.
- Improving the safety of BCG immunotherapy by dose reductionAbrir en una ventana nueva. Eur Urol. 1995;27 Suppl
- Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study.Abrir en una ventana nuevaJ Urol. 1995 Mar;153(3 Pt 2):964-73.
- Resultados preliminares de un estudio randomizado entre Adriamicina y Thio-tepa intravesical en el tratamiento de los tumores superficiales de vejiga. Arch. Esp. Urol., 37,2 (113-122), 1984